DRTG(SH:600329) Guohai Securities·2024-08-15 11:30Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 39.65 billion yuan for H1 2024, a decrease of 3.02% year-on-year, with a net profit attributable to shareholders of 6.58 billion yuan, down 8.97% year-on-year [3][4] - The company has maintained growth in self-operated business despite a high base from the previous year, with self-operated net profit increasing by 2% [4] - The company is focusing on brand building and has made significant progress in developing medical terminals for key products, with some products seeing revenue doubling year-on-year [5] Financial Summary - For 2024, the company is projected to achieve revenues of 84.36 billion yuan, with a growth rate of 3% [8] - The net profit attributable to shareholders is expected to be 11.27 billion yuan, reflecting a growth rate of 14% [8] - The price-to-earnings (P/E) ratio is projected to be 21.12 for 2024, decreasing to 14.38 by 2026 [9]